Betovumeline/fesoterodine (ML-007C-MA) vs NBI-1117570

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Muscarinic M1 and M4 receptors (agonist) · full Schizophrenia pipeline

Betovumeline/fesoterodine (ML-007C-MA)

Developed by MapLight Therapeutics

Phase 2 in Schizophreniasmall molecule
Partial signal

NCT07038876 · Phase 2 · completed

This randomized, quadruple-masked, placebo-controlled Phase 2 trial assigned 307 inpatient adults with an acute exacerbation of schizophrenia 1:1:1 to ML-007C-MA 210/3 mg twice daily, 330/6 mg once daily, or placebo. The primary endpoint was change in PANSS total score at week 5, with each dose compared with placebo. The twice-daily dose improved the score by 4.5 points more than placebo (p=0.015). The once-daily dose improved the score numerically but did not reach statistical significance. One dose met the primary endpoint and one did not, so the result is mixed; the figures come from the sponsor's topline announcement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2030 · NCT07459647 (registry estimate)

Reported efficacy

Change From Baseline to End of Treatment in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline and End of Treatment (5 weeks)): PANSS total score change at week 5 vs placebo (mITT): 210/3 mg BID, LS mean difference -4.5 points, Cohen's d 0.37, p=0.015, met. 330/6 mg QD, numerical improvement, not statistically significant (no figure given), missed. (mixed)

Result source: NCT07038876

NBI-1117570

Developed by Neurocrine Biosciences

Phase 2 in Schizophreniasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT07288333 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBetovumeline/​fesoterodine (ML-007C-MA)NBI-1117570
PANSS total, change—Not reported—Not reported
CGI-S, change—Not reported—Not reported
PANSS response—Not reported—Not reported
PSP, change—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

PANSS total, change

Betovumeline/​fesoterodine (ML-007C-MA)
—Not reported
NBI-1117570
—Not reported

CGI-S, change

Betovumeline/​fesoterodine (ML-007C-MA)
—Not reported
NBI-1117570
—Not reported

PANSS response

Betovumeline/​fesoterodine (ML-007C-MA)
—Not reported
NBI-1117570
—Not reported

PSP, change

Betovumeline/​fesoterodine (ML-007C-MA)
—Not reported
NBI-1117570
—Not reported

Relapse (% of patients)

Betovumeline/​fesoterodine (ML-007C-MA)
—Not reported
NBI-1117570
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NBI-1117570: no structured comparison results are available for Schizophrenia.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Betovumeline/fesoterodine (ML-007C-MA)
PANSS total score change at week 5 vs placebo (mITT): 210/3 mg BID, LS mean difference -4.5 points, Cohen's d 0.37, p=0.015, met. 330/6 mg QD, numerical improvement, not statistically significant (no figure given), missed. NCT07038876 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Betovumeline/fesoterodine (ML-007C-MA)'s landscape · NBI-1117570's landscape